Tempus Real-World Data

Accelerate therapy development with real-world multimodal data

Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.

8.5M+

de-identified research records to power scientific discovery

2M+

records with imaging data

1.5M+

records with matched clinical data linked with genomic information

~400K

records with whole transcriptomic profiles

100x

larger database than The Cancer Genome Atlas, the largest public genomic database

Supporting key development milestones

Discover novel biomarkers

Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities.

Generate & validate hypotheses

Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program.

Design late stage clinical trials

Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility. Plus, conduct trial simulation and survival analysis to support trial success.

The full power of Tempus data at your fingertips

Harness the power of Tempus Lens, enhanced with Tempus One’s conversational AI capabilities, to analyze our extensive library of 8.5M+ de-identified research records. Uncover critical insights that can help accelerate innovation, and improve patient outcomes.

Learn more on our Tempus Lens page →

Inspiring the next wave of oncology research

Explore real research projects that leverage Tempus multimodal data and advanced analytics to tackle complex questions in drug development. Discover novel approaches, understand the full potential of Tempus Lens, and spark new ideas to accelerate your own scientific breakthroughs.

Explore the Lens library →

How we partner

Tempus offers flexible RWD solutions and services

Data collaborations
Work with experienced Tempus scientists and biostatisticians to perform a scoped analysis based on your research objectives and criteria. Receive end-to-end support designing and executing retrospective data analyses.
Advanced analytics
Leverage Tempus Lens to conduct preliminary analyses and identify cohorts of interest, then migrate your records to Workspaces to generate additional insights in our cloud-based coding environment. Layer on AI agents for faster data curation and abstraction.

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

95%

of the top 20 pharma oncology companies* _*Based on publicly available 2024 segment revenue_

250+

biopharma companies

Hear from our partners

We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.

—Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.

—Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.

—Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

—Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

Featured resources

View all resources →

Article

Building the engine to scale data abstraction through AI

Explore the advanced agentic architecture and multi-layered AI system that powers our data abstraction engine, transforming unstructured clinical text into analysis-ready RWD.

Article

AI-enabled data abstraction transforms Tempus data

Discover how our human-in-the-loop framework builds on years of expert abstraction to ensure the quality and accuracy of our AI-structured data.

Article

Q&A: How TechBio and multimodal data are reshaping R&D

Leaders from Tempus and Recursion discuss how their partnership is leveraging AI and massive datasets to accelerate drug discovery and build a new paradigm for precision medicine.

Webinar

Four men's headshots in circular frames within a video player interface.

Driving enterprise value with RWD

Hear from biotech CEOs and VC leaders as they discuss how real-world data can inform strategic decision-making in biotech companies.

Case Study

Document showing 'Indication selection and biomarker strategy' with a pie chart illustrating target prevalence.

Validating a novel target and informing trial design for a first-in-class therapeutic

Discover how a biopharma company used Tempus’ de-identified multimodal data to support validation of a novel target and inform trial design for a first-in-class therapeutic.

Article

Q&A: A chief data officer’s view on powering precision medicine with RWD & AI

Melisa Tucker, Chief Data Officer at Tempus, shares her insights on the current state of healthcare data, Tempus’ approach to building its multimodal library, and how AI is making the vision of a learning healthcare system a reality for researchers and providers.

This is AI-enabled precision medicine

This is the future of healthcare.